We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

284 hedge funds and large institutions have $4.94B invested in Krystal Biotech in 2025 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 106 increasing their positions, 86 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 32

30% more capital invested

Capital invested by funds: $3.8B → $4.94B (+$1.14B)

23% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 86

3% more funds holding

Funds holding: 275 → 284 (+9)

1.08% more ownership

Funds ownership: 95.68% → 96.77% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

63% less call options, than puts

Call options by funds: $43.1M | Put options by funds: $116M

Holders
284
Holders Change
+9
Holders Change %
+3.27%
% of All Funds
3.73%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
46
Increased
106
Reduced
86
Closed
32
Calls
$43.1M
Puts
$116M
Net Calls
-$72.9M
Net Calls Change
-$65.4M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$90.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$30.8M
3
Millennium Management
Millennium Management
New York
+$20.4M
4
ACA
Avoro Capital Advisors
New York
+$17.6M
5
SCM
Soleus Capital Management
Connecticut
+$14.4M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$31M
2
Goldman Sachs
Goldman Sachs
New York
-$27.3M
3
Capital World Investors
Capital World Investors
California
-$19.9M
4
LGM
Logos Global Management
California
-$13.7M
5
Renaissance Technologies
Renaissance Technologies
New York
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
301
Aigen Investment Management
New York
– -$267K -1,944 Closed
OFG
302
OmniStar Financial Group
North Carolina
– -$258K -1,878 Closed
AG
303
Algert Global
California
– -$206K -1,500 Closed
HH
304
Hilltop Holdings
Texas
– -$202K -1,468 Closed
MYIA
305
Mount Yale Investment Advisors
Colorado
– -$172K -1,251 Closed
FDP
306
Financiere des Professionnels
Quebec, Canada
– -$162K -1,182 Closed
Asset Management One
307
Asset Management One
Japan
– -$84.8K -617 Closed
HT
308
Headlands Technologies
Illinois
– -$72.4K -527 Closed
BIG
309
Brooklyn Investment Group
New York
– -$27.8K -202 Closed
Lazard Asset Management
310
Lazard Asset Management
New York
– -$21K -155 Closed
TPWA
311
Twin Peaks Wealth Advisors
California
– -$5.03K -35 Closed
KIM
312
Kestra Investment Management
Texas
– -$1.59K -10 Closed
GWM
313
Geneos Wealth Management
Colorado
– -$1.1K -8 Closed
WWM
314
Wolff Wiese Magana
California
– -$1.1K -8 Closed
TCM
315
Tradewinds Capital Management
Washington
– -$138 -1 Closed
9 10 11 12
13

KRYS Hedge Fund Activity: Q3 2025 in Review

284 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2025, worth a combined $4.94B — up 30% from $3.8B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new KRYS positions and 32 closed out — a net gain of 14 holders — while 106 added to existing stakes and 86 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $90.2M. The largest seller was Braidwell, cutting an estimated $31M.

  • 284 institutional investors held Krystal Biotech (KRYS) as of Q3 2025, up from 275 in Q2 2025.
  • Funds reported $4.94B of Krystal Biotech stock for Q3 2025, up 30% quarter-over-quarter.
  • 46 funds opened new Krystal Biotech positions in Q3 2025 and 32 closed out, a net change of +14 holders.
  • The largest Krystal Biotech buyer in Q3 2025 was Citadel Advisors, an estimated $90.2M added.
  • The largest Krystal Biotech seller in Q3 2025 was Braidwell, an estimated $31M sold.

Based on aggregated 13F filings for Q3 2025.